• Genesis of CKD-MBD: Calcium retention could explain the Hysteresis (Lag in Time) in PTH Involvement.

    Management of CKD-MBD: intermittent administration, as early as CKD stage 2, of parathyroid hormone to prevent the hysteresis, could be an effective management strategy.

    Ref: Pazianas M, Miller PD. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management. J Bone Miner Res. 2020 Dec;35(12):2313-2317.

    Link to Article

  • Osteoporosis in patients with Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

    The label “CKD-MBD/osteoporosis” could be an appropriate term because it emphasizes the renal osteodystrophy component and brings osteoporosis under the official label of CKD-MBD.

    Ref: Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021 Mar 25:S0272-6386(21)00500-X. doi: 10.1053/j.ajkd.2020.12.024. Epub ahead of print. PMID: 33774081.

    Link to Article

  • An oral formulation of teriparatide (PTH 1-34) is being developed by Entera Bio Ltd, for the treatment of hypoparathyroidism and osteoporosis. The company is developing EB 612 (EBP 05) for hypoparathyroidism, and EB 613 for osteoporosis.

    Link to Article